Last reviewed · How we verify
NCT03537222
Quality of Life in Patients With Multiple Myeloma-validation Study
trial testing Myeloma Patient Outcome Scale (MyPOS) in Multiple Myeloma in 58 participants. Terminated before completion.
31 July 2021
Quick facts
| Lead sponsor | Zurich University of Applied Sciences |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 58 |
| Start date | 10 October 2018 |
| Primary completion | 31 July 2021 |
| Estimated completion | 31 July 2021 |
| Sites | 3 locations across Switzerland |
Drugs / interventions tested
- Myeloma Patient Outcome Scale (MyPOS)
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Zurich University of Applied Sciences
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the Myeloma Patient Outcome Scale (MyPOS) will be translated from English to German. This translated version will be quantitatively and qualitatively validated with patients with multiple myeloma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03537222
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Zurich University of Applied Sciences trials
Trials by the same sponsor.
- NCT06037798 — The Cranio-cervical Flexion Test Using the NOD Device · completed
- NCT06003946 — Effectiveness of a Breathing and Relaxation Technique in Antenatal Education · NA · completed
- NCT05960760 — Attitudes Towards Back and Back Pain in German-speaking Switzerland · completed
- NCT04877561 — Test-Retest Reliability of the German Version of the Headache Disability Questionnaire (HDQ). · unknown
- NCT04816357 — Identification of Endometriosis and Migraine Criteria in Women With the Comorbidity of Both Conditions in Comparison Wit · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03537222 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zurich University of Applied Sciences
- Last refreshed: 14 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03537222.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing